BioLargo Inc (BLGO)

Currency in USD
0.1760
+0.0016(+0.92%)
Closed·

BLGO Earnings

Latest Release
Nov 17, 2025
EPS / Forecast
-0.02 / -0.01
Revenue / Forecast
1.10M / 4.10M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2025--/-0.01--/1.2M----Free Sign Up
09/2025-0.02/-0.011.1M/4.1M-100%-73.17%Free Sign Up
06/2025--/--2.78M/4M---30.5%Free Sign Up
03/2025--/--3.27M/5.6M---41.61%Free Sign Up
12/2024-0.006/--3.66M/5.31M---31.07%Free Sign Up
09/2024-0.002/--4.35M/5.22M---16.67%Free Sign Up
06/2024-0.001/--5.01M/4.8M--+4.38%Free Sign Up
03/2024--/--4.76M/4.4M--+8.18%Free Sign Up
12/2023--/--4.37M/4.37M--0%Free Sign Up
09/2023-0.01/-0.012.67M/2.67M0%0%Free Sign Up

All numbers in USD

BioLargo Inc Earnings Call Summary for Q3/2025

  • BioLargo reported a 50% year-over-year revenue decline in Q3 2025, with a $3.85 million credit loss from a Poof dispute, causing shares to fall 7.87% to $0.1699
  • The company maintains a $4.5 million cash position and over $9 million in total assets, despite missing EPS forecasts of -$0.01 and revenue projections of $4.1 million
  • CEO Dennis Calvert remains optimistic about BioLargo's innovation pipeline, noting the company is '95% awesome, 5% pretty much kicking our butt'
  • Strategic focus includes upcoming Clyra Medical products launch, sodium-based battery technology advancement, and PFAS solutions with potential valuation of $60-750 million
  • Management seeks strategic investments and partnerships to support growth initiatives in emerging markets like PFAS remediation and long-duration energy storage
Last Updated: 2025-11-14, 06:04 p/m
Read Full Transcript

FAQ

What Is BioLargo's Earnings Per Share (TTM)?

The BioLargo EPS (TTM) is -0.03.

When Is The Next BioLargo Earnings Date?

BioLargo will release its next earnings report on Apr 06, 2026.

What Is BioLargo’s Revenue Forecasts For Upcoming Quarters?

BioLargo’s revenue forecast is 1.10M.

How Did BioLargo React to the Company's Latest Earnings Report?

BioLargo reported a -100% EPS surprise and a -73.17% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -2.8900%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.